Qyuns Therapeutics Industrialization Base Passes EU QP Audit Meeting EU GMP Standards

Reuters

Oct 10

Qyuns <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Industrialization Base Passes EU QP Audit Meeting EU GMP Standards

Qyuns Therapeutics Co. Ltd. has announced that its subsidiary, Jiangsu Cellularforce Biopharma Co., Ltd., has successfully passed the EU Qualified Person (QP) audit and received the official compliance audit report. This achievement confirms that the company's industrialization base meets EU Good Manufacturing Practice (GMP) standards for pharmaceuticals. The audit, conducted by a senior QP in accordance with EudraLex Volume 4 and related guidelines, recognized Cellularforce's high-standard quality management system, advanced facilities, and professional capabilities. This milestone supports the company's efforts in providing globally compliant biologics CDMO services. No grant or funding involving multiple organizations was mentioned in the announcement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qyuns Therapeutics Co. Ltd. published the original content used to generate this news brief on October 10, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2574122909"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2574122909\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2574122909?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-10 18:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2574122909","market":"nz","top_or_hot":-1,"title":"Qyuns Therapeutics Industrialization Base Passes EU QP Audit Meeting EU GMP Standards","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Qyuns <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Industrialization Base Passes EU QP Audit Meeting EU GMP Standards\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Qyuns Therapeutics Co. Ltd. has announced that its subsidiary, Jiangsu Cellularforce Biopharma Co., Ltd., has successfully passed the EU Qualified Person (QP) audit and received the official compliance audit report. This achievement confirms that the company's industrialization base meets EU Good Manufacturing Practice (GMP) standards for pharmaceuticals. The audit, conducted by a senior QP in accordance with EudraLex Volume 4 and related guidelines, recognized Cellularforce's high-standard quality management system, advanced facilities, and professional capabilities. This milestone supports the company's efforts in providing globally compliant biologics CDMO services. No grant or funding involving multiple organizations was mentioned in the announcement.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qyuns Therapeutics Co. Ltd. published the original content used to generate this news brief on October 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Qyuns Therapeutics Industrialization Base Passes EU QP Audit Meeting EU GMP Standards</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQyuns Therapeutics Industrialization Base Passes EU QP Audit Meeting EU GMP Standards\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-10 18:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Qyuns <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Industrialization Base Passes EU QP Audit Meeting EU GMP Standards\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Qyuns Therapeutics Co. Ltd. has announced that its subsidiary, Jiangsu Cellularforce Biopharma Co., Ltd., has successfully passed the EU Qualified Person (QP) audit and received the official compliance audit report. This achievement confirms that the company's industrialization base meets EU Good Manufacturing Practice (GMP) standards for pharmaceuticals. The audit, conducted by a senior QP in accordance with EudraLex Volume 4 and related guidelines, recognized Cellularforce's high-standard quality management system, advanced facilities, and professional capabilities. This milestone supports the company's efforts in providing globally compliant biologics CDMO services. No grant or funding involving multiple organizations was mentioned in the announcement.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qyuns Therapeutics Co. Ltd. published the original content used to generate this news brief on October 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251010:nNDL8TWJGC:1","article_id":"2574122909","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2574122909","pubTimestamp":1760091566,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Qyuns Therapeutics Co. Ltd. has announced that its subsidiary, Jiangsu Cellularforce Biopharma Co., Ltd., has successfully passed the EU Qualified Person  audit and received the official compliance audit report. This achievement confirms that the company's industrialization base meets EU Good Manufacturing Practice  standards for pharmaceuticals. The audit, conducted by a senior QP in accordance with EudraLex Volume 4 and related guidelines, recognized Cellularforce's high-standard quality management system, advanced facilities, and professional capabilities. This milestone supports the company's efforts in providing globally compliant biologics CDMO services. No grant or funding involving multiple organizations was mentioned in the announcement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02509":"荃信生物-B"},"translate_title":"Qyuns治疗产业化基地通过欧盟QP审核满足欧盟GMP标准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02509":0.9},"content_text":"Qyuns Therapeutics Industrialization Base Passes EU QP Audit Meeting EU GMP Standards\n    \n\n        Qyuns Therapeutics Co. Ltd. has announced that its subsidiary, Jiangsu Cellularforce Biopharma Co., Ltd., has successfully passed the EU Qualified Person (QP) audit and received the official compliance audit report. This achievement confirms that the company's industrialization base meets EU Good Manufacturing Practice (GMP) standards for pharmaceuticals. The audit, conducted by a senior QP in accordance with EudraLex Volume 4 and related guidelines, recognized Cellularforce's high-standard quality management system, advanced facilities, and professional capabilities. This milestone supports the company's efforts in providing globally compliant biologics CDMO services. No grant or funding involving multiple organizations was mentioned in the announcement.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qyuns Therapeutics Co. Ltd. published the original content used to generate this news brief on October 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}